Standard blood tests like a complete blood count or basic metabolic panel cannot diagnose stomach (gastric) cancer on their own, but they can raise red flags that prompt further investigation. Abnormal patterns in routine lab work, particularly iron-deficiency anemia and low albumin, show up frequently in people who turn out to have gastric cancer. Traditional tumor markers like CEA and CA 19-9 exist but catch too few early cases to work as standalone screening tools. The more promising frontier involves newer blood-based technologies analyzing DNA fragments, methylation patterns, and tiny RNA molecules shed by tumors, some of which are detecting early-stage gastric cancer with accuracy rates above 85% in recent studies.
What Routine Blood Work Can Show
A standard complete blood count is not designed to find cancer, but the pattern it reveals in a gastric cancer patient is often distinctive. One Canadian review found that about 40% of patients already had iron-deficiency anemia at the time of their gastric cancer diagnosis, and roughly 59% were anemic by any measure.1PubMed. Iron deficiency anemia in gastric cancer: a Canadian retrospective review A separate single-site study reported similar numbers and noted that by the last follow-up, about four in five gastric cancer patients had developed iron-deficiency anemia, with nearly all eventually needing a red blood cell transfusion.2Journal of Clinical Oncology. Iron deficiency anemia in gastric cancer: A single site retrospective cohort study The anemia develops because gastric tumors bleed, often slowly and invisibly, draining iron stores over weeks or months before anyone suspects cancer.
A large clinical database study went further, cataloging the full routine blood-test fingerprint of gastric cancer. Beyond low hemoglobin and red blood cell counts, patients tended to show wider-than-normal variation in red cell size, higher platelet counts, elevated white blood cell ratios favoring neutrophils over lymphocytes, low albumin and total protein, and mildly elevated liver enzymes.3Journal of Clinical Oncology. The identification of blood pattern for gastric cancer from routine blood tests in a territory-wide big clinical database Those patterns collectively point toward occult bleeding, systemic inflammation, poor nutrition, and in some cases liver involvement from metastatic disease. No single value is diagnostic, but the combination can be enough to make a doctor order an endoscopy.
The practical takeaway is that if your routine blood work shows unexplained iron-deficiency anemia, especially if you are a man or a postmenopausal woman (groups that should not normally be losing iron), your doctor should investigate the gastrointestinal tract as a possible bleeding source. That investigation typically means an upper endoscopy, not more blood tests.
Traditional Tumor Markers and Their Limits
You may have heard of blood tests for “cancer markers,” and indeed several exist for gastric cancer. The most commonly ordered are CEA (carcinoembryonic antigen), CA 19-9 (carbohydrate antigen 19-9), and CA 72-4. These proteins can be elevated when a gastric tumor is present, but their track record for early detection is poor. In one study of 52 gastric cancer patients, the individual sensitivities of CA 72-4, CA 19-9, and CEA at standard cutoff levels were only around 50 to 58%, though combining all three bumped sensitivity up to about 75%.4PubMed Central. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer That still means one in four cancers would be missed even with three markers working together.
These markers also have a serious specificity problem. CA 19-9, for instance, is produced by normal cells in the pancreas, bile ducts, stomach lining, colon, and salivary glands. It can be elevated in a long list of noncancerous conditions including gallstones with bile duct blockage, pancreatitis, pulmonary fibrosis, diabetes, and certain gynecological conditions.5Scientific Reports. Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases One case series documented persistently elevated CA 19-9 in ten patients whose diagnoses ranged from diabetes to obesity to simple indigestion, with no malignancy found.6PubMed. Persistent elevation of serum CA 19-9 with no evidence of malignant disease A review of classic tumor markers in gastric cancer concluded that despite being useful in some clinical scenarios, their role in screening and early diagnosis remains poorly standardized.7PubMed Central. Classic tumor markers in gastric cancer. Current standards and limitations
Where these markers genuinely help is not in finding cancer for the first time but in monitoring patients who have already been diagnosed. If a patient’s CEA or CA 19-9 drops after surgery and then starts climbing again months later, that can signal recurrence before symptoms appear. One study looking at early gastric cancer with lymph node spread found that both CEA and CA 19-9 were significantly elevated in the group with metastases compared to those without, with area-under-the-curve values above 0.92 for both markers in that specific context.8PubMed Central. Computed tomography with carcinoembryonic antigen and carbohydrate antigen 19-9 in diagnosing lymph node metastasis of early gastric cancer But that study was comparing cancer patients with and without lymph node involvement, not healthy people with and without cancer. The distinction matters because tumor markers perform much better at telling apart stages of known disease than at separating cancer from no cancer in the general population.
The Pepsinogen Approach to Risk Stratification
Japan, which has some of the highest gastric cancer rates in the world, pioneered a different blood-test strategy that does not try to detect the tumor directly. Instead, it identifies people whose stomachs have become high-risk environments for cancer. The key tests measure pepsinogen I, pepsinogen II, and gastrin-17, all proteins made by the stomach lining. When the stomach wall becomes chronically inflamed and starts to atrophy (a condition called atrophic gastritis, which is the main precursor to gastric cancer), pepsinogen I levels drop relative to pepsinogen II, and gastrin-17 rises.
A meta-analysis pooling 42 studies found that using a pepsinogen I cutoff of 70 ng/mL combined with a pepsinogen I/II ratio of 3 or less produced a sensitivity of about 77% with a false-positive rate of 27%.9PubMed. Gastric cancer screening using the serum pepsinogen test method The researchers concluded that the pepsinogen test works better as a way to identify high-risk individuals who should then get an endoscopy, rather than as a cancer-detection tool in its own right. A separate study of early-stage gastric cancer patients confirmed that the pepsinogen I/II ratio had an area under the curve of about 0.83 for distinguishing early gastric cancer from non-atrophic gastritis, with 100% sensitivity at a ratio cutoff of roughly 5.10PubMed Central. Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer
Japan has built a practical screening system around these tests. The approach, sometimes called the ABC method, combines pepsinogen levels with a test for Helicobacter pylori antibodies and sorts people into risk groups. Those in the highest-risk group get regular endoscopies; those in the lowest-risk group can be screened less often or not at all. Research has confirmed that H. pylori antibody status combined with pepsinogen levels meaningfully stratifies gastric cancer risk in clinical practice.11PubMed Central. Gastric Cancer Screening by Combined Determination of Serum Helicobacter pylori Antibody and Pepsinogen Concentrations: ABC Method for Gastric Cancer Screening A low pepsinogen I/II ratio is itself a meaningful risk marker for precancerous stomach changes.12Archives of Medical Science. Pepsinogen I, pepsinogen II, gastrin-17, and Helicobacter pylori serological biomarkers in the diagnosis of precursor lesions of gastric cancer The limitation is that the test identifies a risky stomach, not cancer itself. Plenty of people with atrophic gastritis will never develop a tumor. But in high-incidence regions, this approach channels endoscopy resources toward the people who need them most.
Cell-Free DNA and Methylation-Based Blood Tests
The most exciting developments in blood-based gastric cancer detection involve analyzing tiny fragments of DNA that tumors shed into the bloodstream, called cell-free DNA or circulating tumor DNA (ctDNA). These fragments carry chemical signatures, particularly DNA methylation patterns, that distinguish tumor-derived DNA from normal DNA. Several research groups have built tests around this principle and are reporting detection rates that dwarf what traditional tumor markers can achieve.
A plasma-based digital PCR assay using three methylation markers (called STOM eDX) achieved a sensitivity of about 87% and specificity of 90% for detecting gastric cancer. For stage I disease specifically, sensitivity was still roughly 82%, which is remarkable because early-stage tumors shed far less DNA into the blood.13Scientific Reports. Plasma-based digital PCR assay for early detection of gastric cancer using multiple methylation biomarkers A multimodal test called GastroAlert, which combines methylation analysis with other features of cell-free DNA fragmentation, reported even higher performance: an overall area under the curve of 0.965, with a sensitivity of about 90% at 90% specificity. For early-stage disease the area under the curve was 0.948, and stage I sensitivity was about 71%.14PubMed Central. GastroAlert: a multimodal epigenetic blood test for early detection of gastric cancer using cell-free DNA
Another approach focused on the physical structure of cell-free DNA fragments rather than their chemical modifications. By analyzing the size and distribution patterns of these fragments (called fragmentomics), researchers built a model that achieved area-under-the-curve values of 0.97 or higher across training, validation, and external test groups. Sensitivity for stage I gastric cancer exceeded 85% in all groups tested, with specificity above 96%.15PubMed Central. Early detection of gastric cancer with the assistance of cell-free DNA fragmentomics These numbers would make such a test far more useful than any traditional blood marker for early detection.
An important caveat: most of these assays have been validated in carefully selected study populations, not in real-world mass screening. Performance in a study comparing known cancer patients with known healthy controls tends to be better than performance when the test is unleashed on a general population where cancer is rare and confounding conditions are common. The technology is genuinely promising, but it has not yet replaced endoscopy as the gold standard for diagnosis.
MicroRNA and Exosome Tests
Tumors also release tiny RNA molecules, called microRNAs, into the blood. Some of these travel inside small membrane-bound particles called exosomes, which protect them from being broken down. Researchers have been building panels of specific microRNAs whose combined levels can indicate whether gastric cancer is likely present. The advantage of microRNAs is that they are remarkably stable in blood samples and can be measured with relatively straightforward laboratory methods.
A network biology study identified a panel of four circulating microRNAs that could distinguish gastric cancer from both healthy samples and twelve other cancer types, with about 89% sensitivity and 90% specificity.16PubMed Central. Circulating microRNA panels for multi-cancer detection and gastric cancer screening: leveraging a network biology approach A multicenter study called DESTINEX developed a 10-microRNA signature from exosomes that identified stage I (very early) gastric cancer with an area under the curve of about 97%.17JAMA Surgery. Exosomal Liquid Biopsy for the Early Detection of Gastric Cancer: The DESTINEX Multicenter Study Another group found that serum exosomal miR-21 alone had moderate diagnostic power (area under the curve of about 0.77) for early gastric cancer, but combining it with the tumor marker CA 72-4 jumped the area under the curve to 0.93.18PubMed Central. Correlation of serum exosomal miR-21 with the risk of gastric cancer onset: its value for early diagnosis
A separate study using next-generation sequencing identified four exosomal microRNAs whose combined panel, when paired with CEA, achieved an area under the curve of about 0.79 for early-stage gastric cancer. While more modest than some other results, this work confirmed that exosomal microRNAs outperformed any single traditional marker for early diagnosis.19PubMed Central. Combination of Four Serum Exosomal MiRNAs as Novel Diagnostic Biomarkers for Early-Stage Gastric Cancer Circulating tumor cells, actual cancer cells dislodged into the bloodstream, have also been explored. One study found them in about 48% of patients with early gastric cancer or precancerous lesions, compared to only about 5% of controls with benign polyps, yielding a specificity of 95% but a sensitivity of only 49%.20Karger Publishers (Oncology). Circulating Tumor Cells as Diagnostic Markers of Early Gastric Cancer and Gastric Precancerous Lesions That low sensitivity limits their standalone use, but circulating tumor cells may eventually complement other blood-based markers.
An early cost-effectiveness analysis of a microRNA-based screening program found it to be cost-effective, largely because it would improve screening compliance by offering a less invasive alternative to endoscopy.21PubMed. Evaluating the Use of microRNA Blood Tests for Gastric Cancer Screening in a Stratified Population-Level Screening Program: An Early Model-Based Cost-Effectiveness Analysis That matters because many people who should be screened for gastric cancer simply refuse to swallow an endoscope. A blood draw is a much easier sell.
Blood Tests for Monitoring After Treatment
Where blood-based ctDNA testing is arguably furthest along is not in finding new cancers but in tracking patients who have already had surgery. After a gastric tumor is removed, a blood test that detects tumor DNA fragments can reveal whether microscopic disease remains or has returned. A study of patients with resectable gastric cancer found that ctDNA was detectable in about 56% of patients before treatment began, dropping to 15% after surgery. Patients whose ctDNA was still detectable after surgery had dramatically shorter recurrence-free survival, with a hazard ratio above 6 compared to those whose blood cleared.22PubMed Central. Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer A systematic review and meta-analysis of ctDNA in gastric cancer confirmed that serial monitoring after surgery is more sensitive for catching recurrence than a single post-operative test, making a case for repeated blood draws during follow-up.23PubMed Central. Circulating tumor DNA predicts recurrence and assesses prognosis in operable gastric cancer: A systematic review and meta-analysis
This application is closer to clinical use because the bar is different. You are not searching for a needle in a haystack (a rare cancer in a healthy population) but monitoring a known patient for a specific molecular signal. The false-positive problem shrinks considerably in that context. Some oncologists already incorporate ctDNA monitoring into post-surgical follow-up for gastrointestinal cancers, though widespread adoption is still in its early stages.
Why Endoscopy Still Comes First
With all these blood tests in development, it is worth understanding why endoscopy with biopsy remains the definitive way to diagnose gastric cancer. An endoscopy lets a doctor directly visualize the stomach lining and take tissue samples from anything suspicious. A retrospective study at one hospital found that endoscopic diagnosis had 100% sensitivity for detecting malignancy, with 99% specificity.24PubMed Central. Analysis of Histopathological Lesions and Their Correlation With Upper Gastrointestinal Endoscopic Findings: A Retrospective Study at a District Hospital in Ghana No blood test comes close to those numbers, and a biopsy provides the histological diagnosis needed to plan treatment: tumor type, grade, and molecular characteristics that guide therapy choices.
Blood tests are best understood as potential gatekeepers, not replacements. The ideal workflow, which countries like Japan have been refining for decades, uses a blood test to sort the population into risk tiers and then sends the high-risk group to endoscopy. The blood test’s job is not to be perfect. It needs to be good enough to avoid overwhelming endoscopy suites with healthy people while catching most of those who actually need a scope. The pepsinogen-based approach achieves this in high-risk populations. The newer molecular tests may eventually extend this model to populations where gastric cancer is less common but still deadly when caught late.
Who Should Be Thinking About Gastric Cancer Screening
Most Western countries do not have population-wide gastric cancer screening programs because the disease is far less common there than in East Asia. But certain individuals carry elevated risk and should discuss screening with their doctor. These include people with a strong family history of gastric cancer, those with known chronic atrophic gastritis or intestinal metaplasia of the stomach, people of East Asian, Eastern European, or Latin American descent living in higher-incidence regions, and individuals with a history of H. pylori infection that caused significant stomach inflammation. For these groups, periodic endoscopy is currently the standard recommendation.
If your doctor orders routine blood work and finds unexplained iron-deficiency anemia, persistently low albumin, or an unusual pattern of elevated inflammatory markers, those findings alone do not mean you have stomach cancer. They do mean your doctor should look for a cause. In many cases the explanation will be something benign, like a bleeding ulcer or poor dietary iron intake. But in someone with risk factors, those same blood results should prompt a conversation about endoscopy rather than a wait-and-see approach. The difference between finding gastric cancer at stage I versus stage III is enormous in terms of survival, and right now the most reliable way to catch it early is still to look directly at the stomach lining.